Author: Tenforde, Mark W; Olson, Samantha M; Self, Wesley H; Talbot, H Keipp; Lindsell, Christopher J; Steingrub, Jay S; Shapiro, Nathan I; Ginde, Adit A; Douin, David J; Prekker, Matthew E; Brown, Samuel M; Peltan, Ithan D; Gong, Michelle N; Mohamed, Amira; Khan, Akram; Exline, Matthew C; Files, D Clark; Gibbs, Kevin W; Stubblefield, William B; Casey, Jonathan D; Rice, Todd W; Grijalva, Carlos G; Hager, David N; Shehu, Arber; Qadir, Nida; Chang, Steven Y; Wilson, Jennifer G; Gaglani, Manjusha; Murthy, Kempapura; Calhoun, Nicole; Monto, Arnold S; Martin, Emily T; Malani, Anurag; Zimmerman, Richard K; Silveira, Fernanda P; Middleton, Donald B; Zhu, Yuwei; Wyatt, Dayna; Stephenson, Meagan; Baughman, Adrienne; Womack, Kelsey N; Hart, Kimberly W; Kobayashi, Miwako; Verani, Jennifer R; Patel, Manish M
Title: Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged ≥65 Years - United States, January-March 2021. Cord-id: ct4licep Document date: 2021_5_7
ID: ct4licep
Snippet: Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination†with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized a
Document: Adults aged ≥65 years are at increased risk for severe outcomes from COVID-19 and were identified as a priority group to receive the first COVID-19 vaccines approved for use under an Emergency Use Authorization (EUA) in the United States (1-3). In an evaluation at 24 hospitals in 14 states,* the effectiveness of partial or full vaccination†with Pfizer-BioNTech or Moderna vaccines against COVID-19-associated hospitalization was assessed among adults aged ≥65 years. Among 417 hospitalized adults aged ≥65 years (including 187 case-patients and 230 controls), the median age was 73 years, 48% were female, 73% were non-Hispanic White, 17% were non-Hispanic Black, 6% were Hispanic, and 4% lived in a long-term care facility. Adjusted vaccine effectiveness (VE) against COVID-19-associated hospitalization among adults aged ≥65 years was estimated to be 94% (95% confidence interval [CI] = 49%-99%) for full vaccination and 64% (95% CI = 28%-82%) for partial vaccination. These findings are consistent with efficacy determined from clinical trials in the subgroup of adults aged ≥65 years (4,5). This multisite U.S. evaluation under real-world conditions suggests that vaccination provided protection against COVID-19-associated hospitalization among adults aged ≥65 years. Vaccination is a critical tool for reducing severe COVID-19 in groups at high risk.
Search related documents:
Co phrase search for related documents- Try single phrases listed below for: 1
Co phrase search for related documents, hyperlinks ordered by date